Masimo (NASDAQ:MASI) Updates FY 2024 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 4.100-4.100 for the period, compared to the consensus EPS estimate of 4.030. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.1 billion. Masimo also updated its FY 2025 guidance to 4.900-5.100 EPS.

Masimo Trading Down 1.2 %

NASDAQ:MASI opened at $169.94 on Friday. Masimo has a 52 week low of $101.61 and a 52 week high of $180.97. The stock has a market cap of $9.10 billion, a price-to-earnings ratio of 117.20 and a beta of 1.01. The company’s 50 day moving average price is $169.03 and its 200-day moving average price is $139.75. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same period in the previous year, the business posted $0.63 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, equities research analysts forecast that Masimo will post 4.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MASI shares. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Thursday. BTIG Research lifted their price objective on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Raymond James increased their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Wells Fargo & Company lifted their price target on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Piper Sandler increased their price objective on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Masimo currently has an average rating of “Moderate Buy” and an average price target of $179.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.